Treatment of multiple superficial basal cell carcinomas with topical imiquimod
Journal Title: OncoReview - Year 2015, Vol 5, Issue 1
Abstract
Basal cell carcinoma is the most common malignancy of man. The use of the topical imiquimod 5% cream offers a noninvasive, nonsurgical, and an effective option for the treatment of primary types superficial basal cell carcinoma (sBCC). We present a case series of patients who used imiquimod 5% cream with good therapeutic effect. The medication had a good tolerability profile and there were no ocular adverse events. Imiquimod 5% cream could be considered the first choice treatment for BCCs in older patients who are poor candidates to surgery.
Authors and Affiliations
Piotr Brzeziński, Anca Chiriac
Keywords
Related Articles
- EP ID EP67778
- DOI -
- Views 220
- Downloads 0
Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Fu...
Angioplastyka wieńcowa oraz wymiana zastawki aortalnej u dwóch chorych ze szpiczakiem mnogim - opisy przypadków
Szpiczak mnogi jest schorzeniem hematologicznym charakteryzującym się klonalnym rozrostem atypowych plazmocytów, produkujących monoklonalną immunoglobulinę. Roczna zapadalność na niego w Europie wynosi ok. 4,5/100 000 os...
Report from the ESMO Conference on Sarcoma and GIST, 9–10 March 2012, Milan, Italy
In 9–10 March 2012, Milan (Italy), the conference organized by the European Society for Medical Oncology (ESMO) took place. The main topic of the conference was sarcomas and gastrointestinal stromal tumors (GIST). This c...
Central venous catheters and complications in cancer patients
Vascular access has great importance in the treatment of patients submitted to prolonged chemotherapy. We report two patients with early and late complications related to the presence of a central venous catheter. The fi...
A role of JAK in the pathogenesis of Philadelphia negative myeloproliferative neoplasms. Target therapy possibilities
In recent years a significant progress has been made in understanding of the pathogenesis of myeloproliferative neoplasms, especially the one with mutation in JAK2 gene. In 2005 several study groups confirmed the presenc...